Human Genetics of HCV Infection Phenotypes in the Era of Direct-Acting Antivirals - PubMed

Human Genetics of HCV Infection Phenotypes in the Era of Direct-Acting Antivirals - PubMed

Human Genetics of HCV Infection Phenotypes in the Era of Direct-Acting Antivirals

Pierre Nahon 1 2 3, Aurélie Cobat 4 5

Affiliations 

• PMID: 32100095
 
• DOI: 10.1007/s00439-020-02136-4

Abstract

The recent introduction of direct-acting antivirals (DAAs) has revolutionized hepatitis C virus (HCV) therapy by improving virus eradication rates to over 90% in most patient groups. However, the impact of DAAs on global disease burden is currently limited, and a large number of chronically infected individuals remain at risk of developing liver complications, such as liver cirrhosis and hepatocellular carcinoma (HCC). The identification of patients at risk of liver complications and a greater understanding of the biological mechanisms involved in HCV disease progression might improve disease control. Recent genome-wide association and exome sequencing studies have identified several host genetic variants influencing the progression of liver fibrosis and the development of HCC associated with HCV infection and are reviewed here. Interestingly, some of the genetic variants associated with those HCV-associated liver complications were also associated with the clinical course of non-viral chronic hepatitis. Future challenges include the incorporation of this genetic information into clinical risk models for personalized disease management and the study of emerging phenotypes such as liver fibrosis regression and HCC development after HCV eradication.

Similar articles

• Host Genetic Variations Associated With Disease Progression in Chronic Hepatitis C Virus Infection

  K Matsuura et al. Hepatol Res 48 (2), 127-133. Feb 2018. PMID 29235266. - Review

  Treatment with recently developed interferon-free oral regimens combining direct-acting antiviral agents (DAAs) results in the elimination of hepatitis C virus (HCV) in a …
• Declining Hepatitis C Virus-Related Liver Disease Burden in the Direct-Acting Antiviral Therapy Era in New South Wales, Australia

  M Alavi et al. J Hepatol 71 (2), 281-288. Aug 2019. PMID 31078544.

  In the DAA era, there has been a sharp decline in liver disease morbidity and mortality in New South Wales, Australia. AUD remains a major contributor to HCV-related live …
• Impact of Hepatitis C Virus Eradication on Hepatocellular Carcinogenesis

  DK Li et al. Cancer 121 (17), 2874-82. 2015. PMID 26079399. - Review

  Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death in the world. Infection with hepatitis C virus (HCV) represents one of the most common …
• Natural History of Hepatitis C

  RH Westbrook et al. J Hepatol 61 (1 Suppl), S58-68. Nov 2014. PMID 25443346. - Review

  There has long been evidence that hepatitis C can lead to persistent infection in a high proportion of infected individuals, and can progress to chronic liver disease, ci …
• Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection

  K Matsuura et al. Gastroenterology 152 (6), 1383-1394. May 2017. PMID 28163062.

  In a GWAS, we identified the association between the SNP rs17047200, within the intron of TLL1, and development of HCC in patients who achieved an SVR to treatment for ch …